Novo Nordisk CEO Says "Over The Next Quarter Seeing A Steady Flow Of Trial Data For Semaglutide"; "When We Now Launch In New Countries, We Want To Do It In A Way Where We Set Aside A Defined Capacity" For Obesity Drug; "Pleased With" The Catalent...
Novo Nordisk CEO Says "Over The Next Quarter Seeing A Steady Flow Of Trial Data For Semaglutide"; "When We Now Launch In New Countries, We Want To Do It In A Way Where We Set Aside A Defined Capacity" For Obesity Drug; "Pleased With" The Catalent...
Novo Nordisk首席執行官說：“在下一個季度中，Semaglutide的試驗數據將穩步流動”；“當我們現在在新國家推出時，我們希望以一種爲肥胖藥物預留一定容量的方式來做到這一點”；“對Catalent感到滿意”...
Novo Nordisk CEO Says "Over The Next Quarter Seeing A Steady Flow Of Trial Data For Semaglutide"; "When We Now Launch In New Countries, We Want To Do It In A Way Where We Set Aside A Defined Capacity" For Obesity Drug; "Pleased With" The Catalent Acquisition That We're Now Working On And We Expect To Close In This Year
Novo Nordisk首席執行官表示 “在下個季度中，Semaglutide的試驗數據將穩步流動”；“當我們現在在新國家推出時，我們希望以爲肥胖藥物預留一定容量的方式”；“對我們目前正在進行並預計將於今年完成的Catalent收購感到滿意”
- Reuters
-路透社
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。